Ophthalmic Imaging Using Adaptive Optics and OCT

描述（由申请人提供）：本BRP的目的是开发和评估活体眼睛中细胞三维成像技术，并使用该新技术了解与导致世界范围失明的最常见疾病相关的细胞层变化，包括年龄相关性黄斑变性和青光眼。四家机构的合作伙伴将为仪器提供帮助，该仪器结合了提供高横向分辨率的自适应光学（AO）和提供高轴向分辨率的光学相干断层扫描（OCT）。领头的机构是加州大学戴维斯分校（John S. Werner， PI）。在加州大学戴维斯分校和印第安纳大学（Donald T. Miller，现场PI），将开发和测试AO-OCT仪器。杜克大学（Joseph Izatt，网站PI）将开发新的OCT方法，而劳伦斯利弗莫尔国家实验室（Scot Olivier，网站PI）将提供AO方面的前沿进展。这些AO-OCT仪器将允许具有足够分辨率和对比度的人体体内成像，以可视化人类视网膜中最小的细胞。在之前的项目期间，我们使用AO-OCT创建了以前只能通过组织学可见的结构的体积图像，包括光感受器外段，Henle纤维，单个视神经纤维束，黄斑变性患者眼膜内的详细结构，视神经cribosa的精细结构。在这次更新中，我们提出解决新的技术问题，以更充分地挖掘AO-OCT的潜力和功能。工程目标是通过使用自身荧光，双折射，结合“极端AO”技术，以及与血液灌注，视网膜血管中的血红蛋白氧饱和度以及神经元细胞体积中的电变化相关的功能变化来增加细胞结构的对比度。相当大的努力将致力于三维可视化和分割视网膜体积更大的横向和轴向范围比以前可能。工程目标与临床目标平行，即提高我们对与年龄相关性黄斑变性和青光眼标志物相关的细胞变化的理解。这些先进的成像技术将用于评估视网膜和视神经的变化，这些变化是由从失明的主要原因中拯救视网膜层的新疗法引起的。

DESCRIPTION (provided by applicant): The purpose of this BRP is to develop and evaluate technology for three-dimensional imaging of cells in the living eye, and to use this novel technology to understand changes in cell layers associated with the most common diseases leading to world-wide blindness, including age-related macular degeneration and glaucoma. Partners at four institutions will contribute to instrumentation that combines adaptive optics (AO), providing high lateral resolution, with optical coherence tomography (OCT), providing high axial resolution. The lead institution is the University of California, Davis (John S. Werner, PI). Both at UC Davis and at Indiana University (Donald T. Miller, site PI), AO-OCT instrumentation will be developed and tested. Duke University (Joseph Izatt, site PI) will develop novel OCT approaches that will be incorporated, while Lawrence Livermore National Laboratory (Scot Olivier, site PI) will provide cutting-edge advances in AO. These AO-OCT instruments will permit human in vivo imaging with sufficient resolution and contrast to visualize the smallest of cells in the human retina. In the previous project period we have used AO-OCT to create volume images of structures previously only visible with histology, including the photoreceptor outer segments, Fibers of Henle, individual optic nerve fiber bundles, detailed structures within drusen of macular degeneration patients, and fine structure of the lamina cribosa of the optic nerve. In this renewal, we propose to solve new technical issues to more fully tap the potential and functionality of AO-OCT. The engineering goals are directed toward increasing contrast of cellular structures by use of autofluoresence, birefringence, the incorporation of "extreme AO" techniques, and functional changes associated with blood perfusion, hemoglobin oxygen saturation in the retinal vasculature as well as electrical changes in neuronal cell volumes. Considerable effort will be devoted to three-dimensional visualization and segmentation over retinal volumes of larger lateral and axial extent than previously possible. The engineering goals have parallel clinical aims for improving our understanding of the cellular changes associated with markers for age-related macular degeneration and glaucoma. These advanced imaging techniques will be deployed for evaluating the changes in the retina and optic nerve resulting from novel therapies for rescuing retinal layers from the leading causes of blindness.